X

Trial Profile

Efficacy and Safety of a New Leuprolide Acetate 22.5 mg Depot Formulation in the Treatment of Prostate Cancer.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leuprorelin (Primary)
Indications Prostate cancer
Focus Registrational; Therapeutic Use
Sponsors GP Pharm

Most Recent Events

01 Mar 2019 Results investigating the effectiveness, pharmacokinetic properties, and safety of leuprolide acetate for patients with prostate cancer published in the Clinical Therapeutics
12 May 2015 According to GP Pharm media release, Lutrate Depot 22.5 mg was approved through an EU Decentralized procedure.
26 Aug 2013 Planned End Date changed from 1 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com